-
Article type: Cover
2002 Volume 51 Issue 4 Pages
Cover11-
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Cover
2002 Volume 51 Issue 4 Pages
Cover12-
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2002 Volume 51 Issue 4 Pages
App7-
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Kunihiko Tamaki
Article type: Article
2002 Volume 51 Issue 4 Pages
349-351
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Shizuo Akira
Article type: Article
2002 Volume 51 Issue 4 Pages
352-356
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Hideto Asaka, Hirokazu Yoshida, Kohtaro Baba
Article type: Article
2002 Volume 51 Issue 4 Pages
357-363
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
Placebo-controlled outdoors clinical study was performed at the Utsunomiya City Forest Park surrounded by many cryptomerias on March 5,2000, at the season of most cedar pollens, to evaluate the efficacy and its timing and duration of Ebastine. It was a fine weather on the day of the study, and so much cedar pollens as 235 pollens/cm^2 were spreading at the park when it was measured at the park. In particular, the amount of cedar pollen for 2 hours from 10: 00 a.m. when Ebastine was administered exceeded 50 pollens/cm^2 per hour. The nasal symptoms of the placebo-treated subjects promptly aggravated during the time, while the symptoms of the subjects who received oral Ebastine showed the tendency to improve from 2 hours after oral administration under exposure of a large amount of cedar pollens, and the efficacy maintained until 10: 00 a.m. at the next morning that passed 24 hours after administration. The results suggest that Ebastine promptly inhibited the symptom induced by the exposure of a large amount of pollens at the season of most cedar pollens and that once daily oral administration of Ebastine maintained the efficacy at least for 24 hours. It was also suggested that outdoors comparative clinical study at the season of cedar pollen was effective to observe and evaluate the natural clinical course of a patient's symptom and was useful for evaluation of clinical efficacy of anti-pollinosis drugs of various types, including an anti-allergic reagent.
View full abstract
-
Ichiro Terao
Article type: Article
2002 Volume 51 Issue 4 Pages
364-370
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
Bronchial asthma is eosinophilic airway inflammation with enhanced airway responsiveness induced by eosinophilic granule proteins such as eosinophilic cationic protein (ECP) that are released from eosinophils. In the present study using 30 outpatients with mild to moderate asthma who had no history of treatment with steroid inhalation, we examined the effects of 4-week low-dose (200 mg/day) treatment with Uniphyl(R) Tablets, a sustained-release theophylline formulated for once-daily dosing, on airway inflammation and airway hyperresponsiveness, as well as on respiratory function. Uniphyl(R) Tablets significantly (p<0.01) decreased peripheral blood eosinophil count from 647.00 to 444.17/mm^3 and ECP level (geometric mean) from 1318 to 741 ng/ml and improved airway hyperresponsiveness as indicated by a decrease in airway hyperresponsiveness (Dmin, geometric mean) from 1.15 to 6.70units. FEV_<1.0> and PEF showed statistically significant (p<0.01) improvement from 2.39 to 2.69 L and from 6.21 to 7.14 L/sec, respectively. V_<25> and V_<50> also showed statistically significant (p<0.05) improvement. Mean blood theophylline concentration at the time the improvements were seen was 3.95mg/mL. These results suggest that low-dose administration of Uniphyl(R) Tablets has anti-airway inflammatory and anti-airway hyperresponsiveness effects in mild to moderate asthmatic patients.
View full abstract
-
Akiko Aoki, Eri Hagiwara, Shigeru Ono, Atsuhisa Ueda, Takashi Tsuji, Y ...
Article type: Article
2002 Volume 51 Issue 4 Pages
371-374
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Kayoko Suzuki, Toyoshi Harada, Hirohiko Aka-matsu, Kayoko Matsunaga
Article type: Article
2002 Volume 51 Issue 4 Pages
375-378
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Hiroshi Inoue, Kohei Yamauchi, Hitoshi Kobayashi, Yukio Tanifuji
Article type: Article
2002 Volume 51 Issue 4 Pages
379-382
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
The efficacy of the intravenous injection of aminophylline for treatment of acute exacerbations of bronchial asthma has been recognized since 60 years ago by many reports. It has been published on the "Asthma Prevention and Management Guidelines 1998, Japan" as one of important treatment for acute exacerbations of bronchial asthma. An intravenously Administered Theophylline (IAT) was newly developed in Japan in 2000. Different from aminophylline, the theophylline is not combined with ethylenediamine. We investigated efficacy and safety of IAT. In the present study, subjects were 16 asthmatic patients with mild acute exacerbations of bronchial asthma. They were administered IAT (200mg theophylline with 200ml saline) intravenously for two hours. After administration of the IAT, PEF and FEV_1 were increased significantly. And severity of asthma. Borg scale, wheezing and breath sound were improved significantly. It should be emphasized that none of the patients treated in this study had any adverse symptome. The present study suggested that IAT is useful for patients with acute exacerbations of bronchial asthma.
View full abstract
-
Article type: Appendix
2002 Volume 51 Issue 4 Pages
383-384
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2002 Volume 51 Issue 4 Pages
385-
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2002 Volume 51 Issue 4 Pages
386-
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2002 Volume 51 Issue 4 Pages
387-
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2002 Volume 51 Issue 4 Pages
388-389
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2002 Volume 51 Issue 4 Pages
390-
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Appendix
2002 Volume 51 Issue 4 Pages
391-395
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS
-
Article type: Cover
2002 Volume 51 Issue 4 Pages
Cover13-
Published: April 30, 2002
Released on J-STAGE: February 10, 2017
JOURNAL
FREE ACCESS